Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate

These results suggest that carefully scheduled drug combinations that include an agent to antagonize the anti-proliferative effect of IM may prove more efficacious within the Ph+ stem cell compartment than IM monotherapy.